AIM ImmunoTech Inc. (AIM) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

AIM ImmunoTech Inc. (AIM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.19

-0.01 (-7.27%)

At close: Jan 14, 2025, 3:59 PM

0.19

0.00%

After-hours Jan 14, 2025, 08:00 PM EST

undefined% (undefined)

Bid	0.18
Market Cap	12.24M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.47
PE Ratio (ttm)	-0.41
Forward PE	n/a
Analyst	Buy

Ask	0.21
Volume	610,785
Avg. Volume (20D)	534,360
Open	0.20
Previous Close	0.20
Day's Range	0.18 - 0.20
52-Week Range	0.16 - 0.62
Beta	undefined

About AIM

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, n...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 12, 1996

Employees 26

Stock Exchange AMEX

Ticker Symbol AIM

Website https://www.aimimmuno.com

Analyst Forecast

According to 2 analyst ratings, the average rating for AIM stock is "Buy." The 12-month stock price forecast is $2.75, which is an increase of 1333.04% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

AIM ImmunoTech Inc. is scheduled to release its earnings on Apr 1, 2025, before market opens.
Analysts project revenue of $45.00K, reflecting a -30.77% YoY shrinking and earnings per share of -0.1, making a -61.54% decrease YoY.

Why Price Moved

3 months ago · Source

-2.45%

AIM ImmunoTech shares are trading higher after the... Unlock content with Pro Subscription

4 months ago · Source

+15.32%

AIM ImmunoTech shares are trading higher after the company announced the print publication of the data analysis from its early access program studying Ampligen.

News

4 weeks ago · businesswire.com

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that, based on the preliminary vote count of its proxy solicitor, shareholders have elec...

1 month ago · businesswire.com

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders...

1 month ago · businesswire.com

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members

1 month ago · proactiveinvestors.co.uk

Eden Research's regulatory wins keep coming at breakneck pace

Today's announcement that AIM-listed biopesticides developer Eden Research PLC (AIM:EDEN, OTCQB:EDNSF)'s flagship fungicide product Mevalone has been added to the Organic Input List in Germany didn't ...

1 month ago · businesswire.com

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recomme...

1 month ago · proactiveinvestors.co.uk

SDX Energy shares plunge on London delisting plan

SDX Energy PLC (AIM:SDX, OTC:SDXEF) shares plunged around 60% in value on Friday as it announced it intends to exit the London Stock Exchange, delisting from AIM to take up private company status. It ...

1 month ago · businesswire.com

ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has...

1 month ago · businesswire.com

AIM ImmunoTech Refutes Activist Group's False and Misleading Claims

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement refuting the false and misleading claims recently made by a group o...

1 month ago · businesswire.com

AIM ImmunoTech Announces Cash Conservation Plan

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Compensation Committee of the Company's Board of Directors (the “Board”) has es...

1 month ago · businesswire.com

AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation in connection with its upcoming 2024 Annual Meeting of Stockholders the (“An...

1 month ago · proactiveinvestors.co.uk

Shield Therapeutics ‘on track for 2024' - analyst

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s proposed $10 million equity agreement with AOP Health International Management “should provide some much-needed breathing room” for the AIM-listed phar...

2 months ago · seekingalpha.com

AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript

AIM ImmunoTech Inc. (NYSE:AIM ) Q3 2024 Earnings Call Transcript November 15, 2024 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Scientific Officer Conference Call Particip...

2 months ago · seekingalpha.com

Aimia Inc. (AIMFF) Q3 2024 Earnings Call Transcript

Aimia Inc. (OTCPK:AIMFF) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Joe Racanelli - Vice President of Investor Relations Tom Finke - Executive Chairman Steve Leo...

2 months ago · proactiveinvestors.co.uk

Pantheon Resources aims to boost profile with US investors

Pantheon Resources PLC (AIM:PANR, OTCQX:PTHRF) has hired an American investor relations firm as it seeks to woo US investors, ahead of the next wave of progress at the AIM-quoted firm's Alaskan oil an...

2 months ago · proactiveinvestors.co.uk

Inheritance tax raid no death kell for AIM market, says London Stock Exchange exec

The potential removal of inheritance tax relief on AIM-listed shares in the upcoming UK Budget has sparked concerns among investors, with many viewing the change as "painful" and "unnecessary". Howeve...

3 months ago · proactiveinvestors.co.uk

Pulsar Helium to join AIM cashed-up after successful equity raise

Pulsar Helium Inc (TSXV:PLSR, OTC:PSRHF), an explorer focused on acreage in Minnesota, has confirmed the completion of a £3.88 million (C$7 million) equity raise, ahead of joining the AIM market later...